# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

> **NCT02249078** · PHASE1 · WITHDRAWN · sponsor: **Eisai Inc.**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** E6011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02249078
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249078, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02249078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*